KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adaptive Biotechnologies (ADPT) Gains from Sales and Divestitures (2019 - 2025)

Historic Gains from Sales and Divestitures for Adaptive Biotechnologies (ADPT) over the last 7 years, with Q3 2025 value amounting to $3.2 million.

  • Adaptive Biotechnologies' Gains from Sales and Divestitures rose 3118.51% to $3.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.2 million, marking a year-over-year increase of 3118.51%. This contributed to the annual value of $2.6 million for FY2024, which is 7172.62% up from last year.
  • Per Adaptive Biotechnologies' latest filing, its Gains from Sales and Divestitures stood at $3.2 million for Q3 2025, which was up 3118.51% from $3.1 million recorded in Q2 2025.
  • In the past 5 years, Adaptive Biotechnologies' Gains from Sales and Divestitures registered a high of $3.2 million during Q3 2025, and its lowest value of $12500.0 during Q2 2021.
  • Over the past 5 years, Adaptive Biotechnologies' median Gains from Sales and Divestitures value was $1.2 million (recorded in 2023), while the average stood at $1.4 million.
  • As far as peak fluctuations go, Adaptive Biotechnologies' Gains from Sales and Divestitures surged by 152473.07% in 2022, and later skyrocketed by 3118.51% in 2025.
  • Adaptive Biotechnologies' Gains from Sales and Divestitures (Quarter) stood at $18750.0 in 2021, then surged by 1524.73% to $304637.0 in 2022, then surged by 394.64% to $1.5 million in 2023, then soared by 71.73% to $2.6 million in 2024, then increased by 22.35% to $3.2 million in 2025.
  • Its Gains from Sales and Divestitures stands at $3.2 million for Q3 2025, versus $3.1 million for Q2 2025 and $3.0 million for Q1 2025.